Serviços Personalizados
Journal
Artigo
Indicadores
- Citado por SciELO
- Acessos
Links relacionados
- Similares em SciELO
Compartilhar
Revista de investigación clínica
versão On-line ISSN 2564-8896versão impressa ISSN 0034-8376
Resumo
RAMIREZ-CUAPIO, Francisco L. et al. Serum Repressor Element-1 Silencing Transcription Factor Levels in Alzheimer's Patients from a National Institute of Health in Mexico City, Elderly and Young Controls. Rev. invest. clín. [online]. 2021, vol.73, n.1, pp.17-22. Epub 09-Mar-2021. ISSN 2564-8896. https://doi.org/10.24875/ric.20000089.
Background:
Decreased levels of repressor element-1 silencing transcription (REST) factor in the brain, plasma, and neuron-derived exosomes are associated with Alzheimers disease (AD).
Objective:
The objective of the study was to test the viability of serum REST as a possible blood-based biomarker for AD, comparing serum REST levels in AD patients from a National Institute of Health in Mexico City (with different levels of severity and comorbidities), with elderly controls (EC) and young controls (YC).
Methods:
We used an enzyme-linked immunosorbent assay to determine serum REST levels in AD patients (n = 28), EC (n = 19), and YC (n = 24); the AD patients were classified by dementia severity and comorbidities (depression and microangiopathy) using clinimetric tests and magnetic resonance imaging.
Results:
Mean serum REST levels did not differ between AD patients, EC, and YC. The severity of AD and the presence of depression or microangiopathy were not associated with serum REST levels.
Conclusion:
Our results differ from previously published patterns found for plasma and cerebral REST levels. Free serum REST levels may not be a viable AD blood-based biomarker. (REV INVEST CLIN. 2021;73(1):17-22)
Palavras-chave : Aging; Blood-based biomarkers; Dementia; Non-invasive diagnostic tools; Neural-restrictive silencer factor; RE-1 silencing transcription factor.